Square Mile pulls Royal London UK Equity Income rating after weighing up Martin Cholwill successor
While it reinstates recommended rating for Janus Henderson’s £1.1bn UK property fund
Equities
-
-
China looks set to loosen the purse strings again
Following the disappointing string of data in July, the policy mix is turning more dovish
-
UK funds break outflows streak as investors splash £4.8bn in July
July retail flows were nearly three times higher than a year ago
-
High active share key to beating passives as value rally stalls
Just a quarter of active funds outperformed their passive counterparts in Q2
-
Blackrock moves overweight European equities despite industry’s downbeat economic sentiment
Fund buyers meanwhile seem split on the prospects for Europe’s equity market
-
To infinity and beyond: Is space tech the next big investment opportunity?
Commercial space travel fuels interest in nascent sector but fund buyers urge caution
-
Adrian Gosden lands Elite rating from Fundcalibre after passing three-year milestone
Seven funds bag top rating, while two newcomers awarded Elite Radar badges
-
Will tech rally run out of steam as hybrid working becomes the norm?
The ‘easy money’ has already been made but shift away from five-day office era opens up opportunities for new digital disruptors
-
Execs at Woodford darling Oxford Nanopore set for bumper £160m payday
DNA sequencing unicorn reported a £73m pre-tax loss in 2020 despite revenue boost from government contracts for Covid tests
-
Eyes on Boohoo backers as damning report reveals persistent supply chain issues
Five Jupiter funds have punchy positions in fast fashion brand which also features in L&G Growth Trust and Baillie Gifford British Smaller Companies
-
Covid-driven biotech and healthcare run set to continue for investors with high risk tolerance
Schroder Global Healthcare and Axa Framlinton Health Care have returned 519% and 289% over the past decade
-
Terry Smith and Fundsmith Emerging Equities Trust manager initiate fresh holdings
Fundsmith boss alludes to new mystery holding added in July, while Michael O’Brien buys Chinese medical platform and Indian business management provider